Prevention of Atrial Fibrillation After Atrial Flutter Ablation With Ramipril (from the PREFACE Study) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue American Journal of Cardiology Année : 2021

Prevention of Atrial Fibrillation After Atrial Flutter Ablation With Ramipril (from the PREFACE Study)

Frédéric Anselme

Résumé

The clinical efficacy of the inhibitors of the renin-angiotensin-aldosterone system (RAAS) as an upstream therapy for atrial fibrillation (AF) prevention is controversial. No study has itemized so far the role of RAAS inhibitors in AF prevention after atrial flutter (AFL) ablation. This trial aims to investigate the effect of ramipril compared with placebo on AF occurrence in patients hospitalized for AFL ablation without structural heart disease. The Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter (PREFACE) trial was a prospective, multicenter, randomized, double-blind, double-dummy trial depicting the AF occurrence during a 12-month follow-up as the primary end point. A total of 198 patients hospitalized for AFL ablation were enrolled in the trial and randomized to placebo or ramipril 5 mg/day. Patients were followed up during 1 year after AFL ablation using 1-week Holter electrocardiogram at 3, 6, 9, and 12 months. The intention-to-treat population encompassed 97 patients in the ramipril group and 101 patients in the placebo group. The primary end point, such as AF occurrence during the 1-year follow-up, was not different between the 2 groups (p = 0.96). Secondary end points, including the occurrence of supraventricular arrhythmia (p = 0.50), heart failure, stroke, and death, were not different between the 2 groups. Safety outcome parameters, including serious adverse events leading to treatment disruption (p = 0.10), hypotension, impairment of renal function, and elevated serum potassium level, also were not different between the 2 groups. In conclusion, RAAS inhibition using ramipril does not reduce AF occurrence in patients facing AFL ablation during the 1-year follow-up.
Fichier principal
Vignette du fichier
2021 Guichard et al., Prevention of atrial.pdf (25.44 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03414194 , version 1 (04-11-2021)

Identifiants

Citer

Jean-Baptiste Guichard, Frédéric Anselme, Pascal Defaye, Jacques Mansourati, Dominique Pavin, et al.. Prevention of Atrial Fibrillation After Atrial Flutter Ablation With Ramipril (from the PREFACE Study). American Journal of Cardiology, 2021, ⟨10.1016/j.amjcard.2021.09.010⟩. ⟨hal-03414194⟩
21 Consultations
355 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More